Imiquimod treatment of exuberant granulation tissue in a nonhealing diabetic ulcer

Archives of Dermatology

Volumn 141, Issue 11, 2005, Pages 1368-1370

  Lain, Edward L ^a   Carrington, Patrick R ^a,b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCUZYME; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT; IMIQUIMOD; PSEUDOMONIC ACID; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEBRIDEMENT; DIABETIC FOOT; FEMALE; GRANULATION TISSUE; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; WOUND DRESSING; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; DIABETIC FOOT; FEMALE; GRANULATION TISSUE; HUMANS; KERATOLYTIC AGENTS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; WOUND HEALING;

EID: 27944464130     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.141.11.1368     Document Type: Article

References (17)

1. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 1998;134:25-30.
2. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, doubleblind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-721.
3. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-733.
4. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001;44:462-470.
5. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29:15-21.
6. Schwab R, Elston D. Topical imiquimod for recalcitrant flat warts. Cutis. 2000;65:160-163.
7. Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg. 2003;29:1050-1051.
8. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol. 2002;138:1137-1139.
9. Man J, Dytoc MT. Use of imiquimod cream 5% in the treatment of localized morphea. J Cutan Med Surg. 2004;8:166-169.
10. Skinner RB. Treatment of molluscum contagiosum with imiquimod 5% cream. J Am Acad Dermatol. 2002;47:S221-S224.
11. Hemmi H, Kaisho T, Takeuchi S, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
12. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218:74-86.
13. Tough DF. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma. 2004;45:257-264.
14. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol. 2003;121:1205-1209.
15. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437-448.
16. Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res. 2001;96:173-182.
17. Welsh O, Olazaran Z, Gomez M, Salas J, Berman B. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol. 2004;51:639-642.